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Abstract
Healthcare-associated methicillin-resistant Staphylococcus aureus
(MRSA) infection may cause increased hospital stay or, sometimes,
death. Quantifying this effect is complicated because it is a time-
dependent exposure: infection may prolong hospital stay, while longer
stays increase the risk of infection. We overcome these problems by
using a multinomial longitudinal model for estimating the daily prob-
ability of death and discharge. We then extend the basic model to
estimate how the effect of MRSA infection varies over time, and to
quantify the number of excess ICU days due to infection. We find
that infection decreases the relative risk of discharge (relative risk ra-
tio = 0.68, 95% credible interval: 0.54, 0.82), but is only indirectly
associated with increased mortality. An infection on the first day of
admission resulted in a mean extra stay of 0.3 days (95% CI: 0.1,
0.5) for a patient with an APACHE II score of 10, and 1.2 days (95%
CI: 0.5, 2.0) for a patient with an APACHE II score of 30. The de-
crease in the relative risk of discharge remained fairly constant with
day of MRSA infection, but was slightly stronger closer to the start
of infection. These results confirm the importance of MRSA infec-
tion in increasing ICU stay, but suggest that previous work may have
systematically overestimated the effect size.
Medical Subject Headings (MeSH) (keywords): Competing risks,
Intensive Care, Longitudinal analysis, Nosocomial Infections, Time-dependent
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Healthcare associated infections affect 5–10% of acute-care patients in1
developed countries, and considerably more in developing nations (1). These2
infections are direct causes of patient morbidity and mortality, and are also3
believed to lead to increased hospital stays. Many infections are preventable4
by the use of interventions (2). Infections places an important—but poorly5
quantified—burden on health services. Quantifying excess hospital stay is6
essential for assessing how many bed days might be gained from preven-7
tion and subsequent health economic analyses that inform the allocation of8
resources to infection control programmes (3). The recent decision by the9
Centers for Medicare and Medicaid Services to stop re-imbursements to US10
hospitals for selected healthcare associated infections increases the need for a11
valid interpretation of the costs and benefits of infection control interventions12
(4).13
Estimating additional length of hospital stay due to nosocomial infec-14
tions creates a number of statistical challenges (5). The central difficulty15
arises from the fact that infections may increase the length of stay, and in-16
creased length of stay simultaneously increases the chance of infection (6).17
However, most standard regression analyses assume a one-way direction of18
causation from exposure (infection) to response (length of stay). Standard19
survival analysis of hospital stay data is also inappropriate because censor-20
ing of hospital stays due to death does not occur at random. Instead, the21
most severely ill will have the highest chance of dying and the lowest chance22
of being discharged on a given day. Such informative censoring violates the23
2
assumptions of standard survival analyses, and can lead to very large biases24
if unaccounted for. A further problem is that factors that may predispose25
a patient to infection (such as use of invasive interventions) may also be26
independently associated with increased length of stay.27
In this paper we aim to address all these challenges, and to use individual28
patient-level data to quantify the additional length of stay in an intensive care29
unit (ICU) due to infections with one of the most virulent and widely dis-30
tributed nosocomial pathogens, methicillin-resistant Staphylococcus aureus31
(MRSA).32
We make use of a multinomial regression model with a longitudinal data33
format. This format has the advantage of allowing the use of time-dependent34
exposures (i.e. exposures such as assisted ventilation that may change during35
a patient’s stay). Time-dependent exposures can be more informative than36
time-independent exposures because they offer the chance to examine the37
order of exposure and response.38
A further advantage of the longitudinal format is that the effect of time-39
dependent exposures can be allowed to change over time by using time-40
dependent covariates. If modelled with only time-independent covariates, a41
hospital acquired infection would be assumed to decrease the risk of discharge42
by the same amount regardless of the length of time the patient had already43
spent in the ward. In contrast, time-dependent covariates allow changes in44
the exposure effects over time. Thus, for example, the effect of a nosocomial45
infection on the chances of being discharged might be strongest on the actual46
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day of infection and then wane over time.47
The use of time-dependent exposures has been extensively studied in the48
field of longitudinal analyses (7, chapter 12) and in this paper we apply some49
of this knowledge to length of stay data.50
MATERIALS AND METHODS51
Clinical setting52
Data were collected from all patients admitted to two adjacent 15 bed in-53
tensive care units (ICUs) in a 1100 bed dual-site teaching hospital in the54
United Kingdom between January 1st 2002 and April 20th 2006. During55
the study period 60% of the patients were medical, 21% surgical and 19%56
cardiothoracic. Data comprised age, sex, date of admission and discharge57
to ICU, speciality, day 1 Acute Physiology and Chronic Heath Evaluation58
(APACHE)-II score, daily therapeutic intervention scoring system (TISS)59
score (8) which included measurements required to diagnose a systemic in-60
flammatory response syndrome, dates of starting or stopping ventilation or61
hemofiltration, date of collection and culture of MRSA from all microbiolog-62
ical samples, and date of starting treatment with vancomycin or linezolid.63
Clinical samples were only taken when local or systemic infection was sus-64
pected. Further details on infection control and laboratory practice have65
been previously reported (9, 10).66
An MRSA infection was considered to be present if (and only if) three67
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conditions were satisfied: 1) MRSA was isolated from a sterile or non-sterile68
clinical sample including a removed vascular catheter tip; 2) there was treat-69
ment with vancomycin or linezolid which were the only antibiotics used for70
initial treatment of suspected or proven MRSA infection, started between71
1 day before and 3 days after the positive culture; and 3) there was a sys-72
temic inflammatory response syndrome (SIRS) response, requiring 2 of the73
following criteria present between 2 days before and 3 days after the positive74
MRSA culture: temperature < 36 ◦C or > 38 ◦C; heart rate > 90 bpm;75
respiratory rate > 20 breaths/min or PaCO2 < 32 mmHg; white blood cell76
count > 12,000 or < 4,000 cells/mm3 (11). Patients from whom MRSA was77
isolated from any site but who did not fulfil these additional criteria were78
considered to be colonised with MRSA.79
Data quality control80
Data quality control mechanisms included automated range, logic and date81
checks. The integrity of the data extraction process was validated for com-82
pleteness and accuracy by manually comparing 5% of the electronic database83
with the original source data.84
Exposures85
We were motivated to fit a longitudinal model because the data have a num-86
ber of important time-dependent exposures. The most important being the87
5
presence of an MRSA infection, because the primary research question was88
the impact of such infections on length of stay. We carried forward the effect89
of MRSA over time, so once a patient had an MRSA infection their status90
was “yes” for all subsequent days until discharge. This is because we expect91
the effect of an infection to persist; how long the effect persists was one of92
the questions we addressed in the time-dependent covariate model. The list93
of exposures is in Table 1.94
Ethics approval95
The hospital ethics committee waived the need for patient consent and agreed96
to the use of this anonymised patient database for this study.97
Statistical methods98
Daily ICU data were used for all analyses. The table below shows a subset99
of the data for two subjects. Each of the n rows corresponds to one patient100
day on the ICU.101
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ICUID Date TISS Sex Outcome
3154 07 Feb 02 54 F Stayed
3154 08 Feb 02 37 F Stayed
3154 09 Feb 02 40 F Stayed
3154 10 Feb 02 27 F Discharged
3163 09 Feb 02 51 M Stayed
3163 10 Feb 02 39 M Stayed
3163 11 Feb 02 49 M Stayed
3163 12 Feb 02 60 M Died
102
Patient 3154 was admitted to the ICU on February 7th and discharged on the103
10th, giving a length of stay of four days and a final outcome of “Discharged”.104
Patient 3163 was admitted on February 9th and died on the 12th, giving105
a length of stay of four days and a final outcome of “Died”. The TISS106
score (a measure of the level of patient care required) is a time-dependent107
exposure which changed from day-to-day (8). The nominal response variable108
“Outcome” describes each patient’s day-to-day status (stayed, discharged or109
died). We assumed this nominal response had a multinomial distribution,110
and so examined the probability of “Stayed”, “Discharged” and “Died” for111
the ith patient day (i = 1, . . . , n), denoted as pii1, pii2 and pii3 respectively112
(12, Chapter 8). We were interested in the association between these three113
probabilities and the exposures, hence we used a nominal logistic regression114
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(or multinomial) model defined as115
pˆii1 =
1
1 + exp (ri2) + exp (ri3)
, i = 1, . . . , n,
pˆiij =
exp (rij)
1 + exp (ri2) + exp (ri3)
, i = 1, . . . , n, j = 2, 3,
rij = x
T
i bj , i = 1, . . . , n, j = 2, 3, (1)
where xi is a set of exposures for row i of the data and bj is the vector of116
parameters for outcome j (bj1, . . . , bjp), where j = 2 represents ICU discharge117
and j = 3 represents death. The above formulation satisfies the multinomial118
assumption that pii1 + pii2 + pii3 = 1.119
The exponential of bjk gives the relative risk ratio, for a one unit increase120
in the values of covariate k, of being in category j = 2, 3 relative to category121
j = 1 (staying), given that the other covariates are held constant. For122
example, a value of exp(b2,5) = 2 would mean that the relative risk of being123
discharged would be twice as likely than staying when covariate 5 is increased124
by one. A relative risk ratio is similar to an odds ratio, but is necessarily125
more complicated because of the multiple response categories.126
This nominal logistic regression model can be thought of as a discrete127
time longitudinal survival model (13, Section 10.2.3) and is closely related to128
a competing risks model (14). To realise this, consider that the multinomial129
model estimates the probability of death or discharge on each day. Similarly,130
if we used a competing risks model we would estimate the probability of131
death or discharge in a short period of time. Previous work has shown the132
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similarity between a logistic longitudinal survival model (i.e., j = 1, 2) and133
Cox regression (15). We have extended this similarity by changing the logistic134
model to a nominal logistic model, and the Cox regression to a competing135
risks model.136
One advantage of using a nominal logistic model with a longitudinal struc-137
ture is the ability to incorporate random effects. These are useful for mod-138
elling heterogeneity and allow the model to account for some of the large un-139
explained variation in length of stay. We considered models with a random140
intercept for each patient admission, allowing the probability of discharge141
and death to vary between admissions. The regression equation (1) becomes142
rij = x
T
i bj + zsjI(si = s), i = 1, . . . , n, j = 2, 3,
where zsj is the random intercept for admission s for discharge (j = 2) and143
death (j = 3). As before, we do not need to specify an intercept for the144
reference category (j = 1). The I() is an indicator function which matches145
the admission number on row i of the data to admission s. We used a mul-146
tivariate Normal distribution to create each admission’s death and discharge147
intercept148
zs ∼ N(0,Ω), s = 1, . . . , m,
where Ω is a 2× 2 variance–covariance matrix and m is the total number of149
subjects.150
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We also considered models with time-dependent covariates, allowing the151
effect of MRSA infection on subsequent ICU stay to vary with the number152




i bj + x
′
icjdI(di = d), i = 1, . . . , n, j = 2, 3, (2)
where x′i is a time-dependent exposure and di is the days since ICU entry for155
row i of the data. The parameter cjd is then the effect of x
′
i on day d, and is156
estimated separately for discharge (j = 2) and death (j = 3). We estimated157
the cjd parameters as Normally distributed random effects given by158
cjd ∼ N(µc, σ
2
c ).
Because the number of patients not discharged or dead becomes small as d159
becomes large, we truncated the time-varying intercept after 21 days. So for160
d ≥ 22, cjd = cj22.161
Equation (2) can also be used to model a lagged effect for a time-dependent162
covariate if d is defined as the number of days since x′i equalled X. This163
lagged effect allows the effect of the covariate to change after a specific event164
(x′i = X). In this analysis, we allowed the effect of MRSA infection to vary165
with the time since first infected, because we were interested in whether the166
effect of the MRSA infection on discharge waned with increasing time since167
infection.168
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Estimating the extra length of stay169
To calculate the excess length of stay due to infection on day d we subtracted170
the survivor functions from the day of infection onwards using171
E(excess LOS|MRSA on day d) =
m∑
t=d
S(t|MRSA on day d)−S(t|no MRSA).
We only evaluate the sum up to some limit m, as for large values of t the172
survivor functions become very small. In this analysis we use a limit of173
m = 21 days. We estimated the survivor function at day t by multiplying174
the probabilities of staying from day 1 up to day t,175
S(t) = pij1(t
′ = 1,xj)× pij1(t
′ = 2,xj)× . . .× pij1(t
′ = t,xj)
where xj is a set of covariates (we have used a different notation to that above176
to emphasise the dependence of the probability on time and the covariates).177
We estimated the excess length of stay for an infection occurring during each178
of the first 21 days in ICU, and for three different Day 1 APACHE II scores:179
10, 20 and 30, reflecting a range of morbidity.180
Model fitting and building181
We fitted a number of different models using the model extensions detailed182
above using the same set of exposures for each model (Table 1). We selected183
the best fitting model using the deviance information criterion (DIC). A dif-184
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ference in DIC of 10 is considered substantial (http://www.mrc-bsu.cam.ac.uk/185
bugs/winbugs/dicpage.shtml).186
The models were fitted in a Bayesian framework using the WinBUGS187
package (16), using vague priors for all unknown parameters. We used a188
vague Normal prior with zero mean and variance of 1000 for all regression189
parameters, and a gamma prior with a shape and inverse scale parameter of190
0.001 for all inverse-variance parameters.191
Missing data192
As shown in Table 1, there was some missing data for the TISS score, and193
just three missing scores for the day 1 APACHE II. The TISS scores were194
most often missing on the day of a patient’s discharge or death. To prevent195
these important days from being lost from the analysis we imputed the TISS196
scores using a random effect for each admission given by197
xik ∼ N(µi, σ
2
w), i = 1, . . . , n, k = 1, . . . , mi,
µi ∼ N(µ, σ
2
b ), i = 1, . . . , n,
where mi is the number of days observed for subject i, µi is the mean score198
for each subject, and σ2b and σ
2
w estimate the between- and within-subject199
variance, respectively. This imputation was made in WinBUGS in tandem200
with the estimation of the parameters governing discharge and death. In201




There were 4569 separate admissions leading to 44,505 days spent on the205
ICU. Lengths of patient stays ranged from 0 to 363 days, and were highly206
skewed with a mean (SD) of 8.8 (14.1) days and a median (IQR) of 4 (2, 11).207
MRSA was cultured from 864 patients of which 335 developed an MRSA208
infection which led to 6696 infected days: 15.0% of the total patient-days on209
the ICU. One-hundred and six (31.6%) of the 335 admissions who developed210
an MRSA infection died, compared with 916 out of 4234 (21.6%) of the211
admissions without an MRSA infection.212
We fitted seven different models to the data and they are compared using213
the DIC in Table 2. Model I had no random intercepts or time-dependent214
covariates (see table 1 for list of exposures). Model II built on Model I by215
including a time-dependent intercept to account for the fact that risk of death216
or discharge might vary during a patient’s stay on ICU. This decreased the217
DIC by 710 indicating a substantially improved model fit. The probabilities218
that a patient stayed, died or was discharged during the first 21 days in ICU219
are shown in Figure 1. The most notable feature is the change from a low220
probability of discharge of 0.08 on the day of admission (day 0) to a peak in221
discharge probability on day 1 of 0.29. After day 1 the daily probability of222
discharge gradually decreases with increasing stay. The probability of death223
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is small on any day, ranging between 0.01 and 0.02.224
Model III extended Model II by adding random admission-specific in-225
tercepts to account for between-admission variation not explained by other226
covariates. This addition improved the model fit greatly as the DIC decreased227
by 520 (Table 2).228
Model IV built on Model III by allowing the effect of MRSA infection229
on death and discharge to vary depending upon when it occurred over the230
first 21 days after ICU admission. This addition worsened the model fit as231
the DIC increased by 10 (Table 2). The time-dependent MRSA estimates232
for the daily relative risk ratios of discharge and death are shown in Figure233
2. MRSA infection was associated with a decreased risk of discharge, and234
this decrease was similar regardless of whether the MRSA infection occurred235
early or late in a patient’s stay. The mean relative risk ratio of discharge236
after becoming infected with MRSA was 0.78 (95% CI: 0.62, 0.97) relative237
to an MRSA free patient. Developing an MRSA infection had little direct238
effect on the risk of death (RRR = 1.12, 95% CI: 0.88, 1.38).239
Model V extended Model III by allowing the effect of MRSA infection on240
death and discharge, to vary from the day the infection started to examine241
whether the effect waned over time. This addition improved the model fit as242
the DIC decreased by 30 (Table 2). The time-dependent MRSA estimates243
for discharge and death are shown in Figure 3. The mean relative risk ratio244
of discharge after an MRSA infection was 0.76 (95% CI: 0.60, 0.97) relative245
to an MRSA free patient. There was a slight decrease in the effect of an246
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MRSA infection with increasing time since infection: during the first five247
days after infection the mean relative risk ratio of discharge was 0.73, while248
10 days after infection it was 0.77. Again, there was little evidence that249
MRSA infection had a direct effect on the risk of death (RRR = 1.16, 95%250
CI: 0.95, 1.37). This result is considered further in the discussion.251
Models I–V all adjusted for the daily TISS score. We were concerned that252
TISS score could be affected not only by the underlying severity of patient253
illness but also by MRSA infection. If this were the case, adjusting for the254
daily TISS score would bias the estimate of the effect of MRSA on death and255
discharge (18), possibly causing the model to miss a true association between256
MRSA and death. We therefore fitted two more models (Model VI and VII).257
Model VI was as Model V, but adjusted for day 1 TISS only, instead of daily258
TISS. The effect of MRSA infection on death changed little, but the relative259
risk ratio of discharge strengthened to 0.69 (95% CI: 0.55, 0.84). Model VII260
was as model III, but without any adjustment for TISS score, the effect on261
discharge was similar, RRR = 0.68 (95% CI: 0.54, 0.82).262
The risk ratios of death and discharge relative to staying from Model VII263
are shown in Table 3. The strongest reduction in the risk of discharge was264
associated with ventilation, while haemofiltration was associated with the265
strongest increase in the risk of death. There was little evidence of difference266
in the risks of discharge or death between the five specialty categories. The267
risk of discharge varied by day of the week, being significantly lower on the268
weekend compared to Wednesday.269
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Figure 4 shows the relative risk ratio of discharge and death after an270
MRSA infection for the seven different models. For models IV to VI the271
effect plotted is the mean over all times. Including a time-dependent intercept272
greatly changed the effect of MRSA infection as shown by the differences in273
relative risk ratios between models I and II. Adding a random intercept meant274
that the effect of MRSA significantly decreased the risk of discharge (Model275
III compared with Model II). Models IV and V had similar mean relative276
risk ratios to Model III, but with slightly wider credible intervals. Models277
VI and VII showed the strongest reduction in the risk of discharge risk after278
MRSA infection.279
Figure 5 shows the mean excess length of stay due to an MRSA infection280
according to day 1 APACHE scores. For an infection on day 1, a patient281
with an APACHE II score of 10 would have a mean extra length of stay of282
0.3 days (95% CI: 0.1, 0.5). A sicker patient with an APACHE II score of 30283
would a longer stay of 1.2 days (95% CI: 0.5, 2.0).284
DISCUSSION285
MRSA infection had little direct effect on risk of death (Figure 4; model286
VII RRR = 1.14, 95% CI: 0.93, 1.39). However, all the models considered287
indicated that infection indirectly contributed to increased mortality. This288
occurs because patients with MRSA infections tend to stay longer in the ICU,289
and each day in the ICU has an associated mortality risk. Such an indirect290
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link has also been found between nosocomial pneumonia infection and death291
(19).292
All seven multinomial models considered found that MRSA infection de-293
creased the risk of discharge. While the magnitude of this effect varied con-294
siderably between models, the three models which gave (by some margin) the295
best fits to the data (III, IV and V) all yielded remarkably similar estimates:296
patients with MRSA infections had a relative risk of discharge (compared297
to staying) that was about 20% lower than that for patients without MRSA298
infections.299
Additional stay attributed to the MRSA infection was found to be higher300
for sicker patients (as measured by the APACHE II score) and for infections301
occurring earlier in the ICU stay (Figure 5). The mean excesses are for302
all admissions, so infections occurring at later times have a much smaller303
attributable cohort and so cause less overall excess stays. Sicker patients304
have less physical reserve and may be less able to cope with an infection,305
hence their increased length of stay after infection compared with healthier306
patients.307
One potential drawback of our approach is the retrospective nature of308
the infection diagnosis based on SIRS criteria, antibiotic start and culture of309
MRSA from a clinical site. This led to a diagnosis of MRSA infection in 335310
(39%) of 864 patients colonized with MRSA, which although high is likely311
to be explained by the particular virulence of MRSA compared with other312
hospital bacteria and the hyperinvasive nature of the TW MRSA strain that313
17
was circulating on the ICU at that time (9).314
Our approach to estimating additional length of stay caused by hospital315
infections overcomes the pitfalls that affect much of the literature, and we316
believe it should therefore provide more reliable estimates. However, an317
alternative analytical approach would have been to use a multistate model318
(14, 19, 20).319
Such multistate models can be used to model the flow of patients through320
a set of defined states. For example, patients may start in the “hospital en-321
try” state, some may subsequently move to an “infected” state, and then322
to a “discharged” state. However, an important advantage of the approach323
we used is the relative ease of incorporating lagged covariates and random324
effects. Nonetheless, the two approaches have similarities, and the multino-325
mial model used in this paper can be thought of as a discrete time analogue326
of a multistate model (when comparable models could be fitted, they were327
in fact found to give very similar results). One potential drawback of the328
multinomial model is that the data must be equally spaced, and in our case329
all times were rounded to the nearest day. However, the model could be330
readily extended to smaller time-steps if required and data were available.331
The aim of this work was to estimate the degree to which MRSA infection332
causes increased length of stay, rather than to simply document associations.333
This raises important issues about identifying confounders. Controlling for334
the time-dependent exposure of daily TISS score gave a better fit to the data335
(Table 2), but it is also likely that MRSA infection will have an effect on the336
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TISS score, particularly through prompting new antibiotic starts, catheter337
insertions and treatment with vasoactive agents. Therefore adjusting for338
the daily TISS score in the model would not only be unnecessary, it would339
be potentially actively harmful and introduce bias (18). This consideration340
motivated Models VI (which includes only the day 1 rather than the daily341
TISS score) and Model VII (without any TISS score), which are therefore342
not vulnerable to this problem. These models showed an increased effect of343
MRSA infection on discharge compared with the other models with time-344
dependent covariates (Figure 4) (18).345
Being able to compare the fit of the models using the DIC is one of346
the advantages of using a Bayesian framework (Table 2). One surprising347
result was the reduction in the effective number of parameters from 2208 for348
Model V to 1604 for Model VI, when the only change was fitting TISS as349
a time-independent, instead of time-dependent, covariate (hence we might350
have expected a reduction of around 40 parameters). The large reduction in351
the effective number of parameters is due to the day 1 TISS score explaining352
a lot of the between-admission variation in the risk of discharge and death.353
This variation is no longer modelled by the random subject intercept, and so354
many less parameters are needed. Nonetheless, despite the poorer fit to data355
as measured by the DIC, knowledge of the likely causal pathways suggests356
that models VI and VII would give the most reliable estimate of the impact357
of MRSA infection on length of stay.358
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Figure 1: Probability that a patient stayed, was discharged or died by days
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Mean probabilities from model II for a female patient aged 60, with a day 1 APACHE II of 20, daily TISS
of 40, who is not ventilated or filtrated, in the specialty category of Medicine + Acute Renal Failure +
Cardiology
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Figure 2: Daily relative risk ratio of discharge and death from ICU relative
to staying after an MRSA infection dependent on the time delay between
admission and infection (estimates from model IV)




































intensive care unit (ICU), Methicillin-resistant Staphylococcus aureus (MRSA), relative risk ratio (RRR)
Mean relative risk ratio and 95% credible interval. Horizontal line at relative risk ratio of 1.
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Figure 3: Daily relative risk ratio of discharge and death from ICU relative
to staying after an MRSA infection by days since infection (estimates from
model V)
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Figure 4: Overall daily relative risk ratio of discharge and death from ICU
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Figure 5: Mean excess length of stay due to an MRSA infection by day of
infection and Day 1 APACHE II score (estimates from model VII)


























Table 1: Exposures Used and Descriptive Statistics
Time-
Covariate (category) dependent Type Missing Statistics†
Age No Continuous 0 60 (17.5)
Sex (male) No Binary 0 2815 (61.6)
Speciality No Nominal 0
Day of week Yes Nominal 0
Day 1 APACHE II No Continuous 3 (0.1%) 17.2 (8.0)
TISS Yes Continuous 3844 (8.6%) 40.7 (13.4)
Ventilation (yes) Yes Binary 0 33,015 (74.2)
Haemofiltrated (yes) Yes Binary 0 7408 (16.6)
MRSA infection‡ (yes) Yes Binary 0 6696 (15.0)
acute physiology and chronic health evaluation (APACHE), credible interval (CI), Methicillin-resistant
Staphylococcus aureus (MRSA), therapeutic intervention scoring system (TISS)
† Mean (standard deviation) for continuous covariates, number (% of patients) for sex and number (% of
days) for binary time-dependent covariates
‡ MRSA carried forward from day of infection to all subsequent days
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Table 2: Comparing Different Models Using the Deviance Information Criterion
Effective
Number of Mean Difference
Model parameters deviance DIC in DIC†
I) No time-dependent covariates or random intercepts 333.0 27,070 27,400
II) Model I + time-dependent intercept 382.6 26,310 26,690 710
III) Model II + random admission intercepts 2148 24,020 26,170 520
IV) Model III + time-dependent MRSA 2117 24,060 26,180 −10
V) Model III + lagged time-dependent MRSA 2208 23,930 26,140 30
VI) Model V − daily TISS + day 1 TISS 1640 25,370 27,370 −1230
VII) Model III − daily TISS 1649 25,750 27,400 −3340
deviance information criterion (DIC)
† Lower numbered model minus higher. A lower DIC indicates a better model fit; a difference in DIC of 10 is considered substantial.
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Table 3: Relative Risk Ratios (and 95% credible intervals) of Daily Discharge and Death Relative to Staying.
Estimates from Model VII.
Discharge Death
Variable (units) RRR 95% CI RRR 95% CI
Age (10 year increase) 0.93 0.90, 0.96 1.13 1.08, 1.18
Sex (Male vs Female) 1.12 1.01, 1.25 0.81 0.71, 0.93
Day 1 APACHE II (5 point increase) 0.66 0.63, 0.69 1.32 1.25, 1.40
Ventilated (yes vs no) 0.05 0.04, 0.06 1.63 1.36, 1.99
Heamofiltration (yes vs no) 0.30 0.25, 0.36 1.80 1.56, 2.08
MRSA infection (yes vs no) 0.68 0.54, 0.82 1.14 0.93, 1.39
Speciality† (Surgery) 0.87 0.74, 1.01 1.07 0.89, 1.29
Speciality† (Cardiothoracic surgery) 0.94 0.80, 1.09 1.02 0.85, 1.23
Speciality† (Orthapaedics) 0.84 0.55, 1.24 1.21 0.67, 1.95
Speciality† (ITU referrals) 0.93 0.78, 1.11 1.14 0.93, 1.39
Day of the week‡ (Monday) 0.89 0.77, 1.05 0.85 0.68, 1.07
Day of the week‡ (Tuesday) 0.94 0.81, 1.11 0.95 0.76, 1.18
Day of the week‡ (Thursday) 1.00 0.85, 1.17 0.91 0.72, 1.14
Day of the week‡ (Friday) 1.06 0.92, 1.24 0.93 0.73, 1.17
Day of the week‡ (Saturday) 0.72 0.62, 0.86 0.90 0.72, 1.13
Day of the week‡ (Sunday) 0.63 0.53, 0.75 0.98 0.78, 1.24
acute physiology and chronic health evaluation (APACHE), credible interval (CI), Methicillin-resistant Staphylococcus aureus (MRSA), relative risk
ratio (RRR), therapeutic intervention scoring system (TISS)
† Reference category = Medicine + Acute Renal Failure + Cardiology
‡ Reference category = Wednesday
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